RJA
FBRX icon

Raymond James & Associates’s Forte Biosciences FBRX Stock Holding History

Raymond James & Associates’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-40
Closed -$142K – 3667
2018
Q2 		$142K Buy
+40
New +$146K ﹤0.01% 3345

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Raymond James & Associates's FBRX Position: Q3 2018 in Review

Raymond James & Associates sold out of Forte Biosciences (FBRX) in Q3 2018, closing a stake of 40 shares — an estimated $142K sold.

Raymond James & Associates first reported a position in FBRX in Q2 2018 and held it in 1 quarter. The position peaked at $142K in Q2 2018. 63 funds tracked by Wall St. Rank hold FBRX as of Q3 2018.

  • Raymond James & Associates reported no remaining Forte Biosciences position as of Q3 2018 after selling out during the quarter.
  • Raymond James & Associates sold 40 Forte Biosciences shares in Q3 2018, an estimated $142K.
  • Raymond James & Associates first reported a position in Forte Biosciences in Q2 2018 and held it in 1 quarter.
  • Raymond James & Associates's Forte Biosciences position peaked at $142K in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2018.

Based on Raymond James & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.